
Innoviva (INVA) Stock Forecast & Price Target
Innoviva (INVA) Analyst Ratings
Bulls say
Innoviva is poised for growth with a diverse portfolio of royalty healthcare assets, a strong financial performance, and a focus on developing innovative treatments for antibiotic-resistant infections and depression. Their products, including Xacduro and Giapreza, have shown promising clinical results and are filling crucial gaps in the healthcare market. Additionally, Innoviva is adapting to the changing landscape of healthcare with the implementation of telemedicine and at-home test kits.
Bears say
Innoviva is facing multiple challenges in its royalty portfolio, with potential competition from new drugs such as Blujepa and Nuzolvence for ESBL and carbapenem-resistant infections. Additionally, while their acquisitions of Lyndra and Syndeio Biosciences offer potential for oral dosing and treatments for synaptic diseases, the success of these drugs is uncertain and may not provide significant financial gains. The company's reliance on one major royalty contributor, GlaxoSmithKline, poses a significant risk to their income if there were to be any issues with the performance of GlaxoSmithKline's products in the market.
This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.
Innoviva (INVA) Analyst Forecast & Price Prediction
Start investing in Innoviva (INVA)
Order type
Buy in
Order amount
Est. shares
0 shares